Flagship Protein A Resins from Cytiva Increase Flexibility and Accessibility for Clinical and Commercial Scenarios
- New affinity chromatography resins offer process economy in the capture step
- In clinical scenario, new resins can reduce consumable cost per gram of mAb by over 30% compared to legacy MabSelect SuRe LX resin1
- Different protein A resins are suited for different stages of drug development and manufacturing
Two new resins launched in 2025 by Cytiva, a Danaher company and a leader in the life sciences industry, are pioneering flexible solutions for the biopharma sector. By answering market needs for cost efficiency with high performance in low-demand production, MabSelect SuRe 70 and MabSelect PrismA X expand Cytiva’s industry-leading resins portfolio.
Susana Campos Agramonte, head of Downstream Process Development, 3P BIOVIAN, says: “We tested the PrismA X resin in a process under development, and it outperformed the other resins evaluated. This resin demonstrated cost efficiency while meeting our process requirements. Cytiva has provided an innovative tool to support the advancement of our new projects.”
Sofie Stille, Vice President and General Manager, Resins and Technologies, Cytiva, says: “Our PrismA X resin started life as a custom project, then we realized how its technical capabilities could be expanded to bring value to more customers. In our complete portfolio of protein A resins, our combination of ligand and base matrix is a powerful toolkit for customers to run at whatever scale and titer they need. And importantly, because they offer long life and process efficiencies, these resins can help drive down Cost of Goods sold (CoGS).”
Differentiated affinity chromatography resins
Regular monoclonal antibodies are the largest biopharmaceutical used in medicine today. To meet the increasing mass and productivity demanded in today’s market, downstream intensification is required. During this step, affinity chromatography is essential for purifying antibodies, fragments, and bispecifics. The optimal resin depends on the specific scenario and priorities of the manufacturer.
Flexible options for varied manufacturing needs
Cytiva’s protein A resins offer advantages for customers’ priorities in terms of cost, speed, yield, and purity.
- MabSelect SuRe 70 and MabSelect PrismA X offer options to benefit low demand production (i.e. clinical production), complementing MabSelect PrismA advantages for short processing time important in commercial manufacturing.
- Affinity resins with novel ligands or compatibility with special process conditions are available for bispecifics, fragments, and other antibody derived-entities such as MabSelect VL, MabSelect VH3, and MabSelect mild elution resins.
MabSelect SuRe 70 has the highest Dynamic Binding Capacity (DBC) of Cytiva’s MabSelect SuRe resins and is well-suited for low demand production, commonly used in clinical production and in small biotech companies. It delivers cost efficiency with Cytiva quality and support.
In commercial manufacturing, resins typically comprise about 3% of process cost, and speed and alkaline stability become higher priority in the search for process efficiency. MabSelect PrismA X and MabSelect PrismA have industry-leading alkaline stability, enabling efficient cleaning and sanitization for 200 cycles in 0.5 M NaOH for improved process economy and robustness. MabSelect PrismA resin offers short processing times due to the beneficial pressure-flow properties.
Processing time in clinical scenario. Note: The modeling uses fixed column diameters and residence times, meaning scenarios will be realistic but not fully optimized. Degree of optimization will vary substantially between resins, so outputs may not be fully representative.
* DBC based on benchmark study. All tests were done in pentuplicates (five columns) with mAb. Pressure flow properties used are based on vendor specifications. Assuming no decline in capacity during the lifetime. However, a decline in DBC will occur and be dependent on the resin used and the cleaning protocol.
* PRAESTO is a registered trademark of Purolite Corporation. No approval or endorsement by Purolite Corporation is implied.
Heritage of excellence and sustainability
Since the discovery of protein A in 1958, Cytiva has been at the forefront of innovation in protein purification tools. From the 1980s’ industrial antibody production to the 2000s’ higher throughput and productivity, and now to the 2020s’ multiproduct manufacturing, Cytiva leads the industry on innovation in chromatography resins, holding more than 750 patents.
Integrating eco-design principles into resin product development helps reduce the environmental impact and overall costs during the product’s life cycle. Therefore, recent innovations are characterized by enhanced efficiency and reduced resource consumption, requiring fewer chemicals and less water during production.
Security of Supply
Beyond the additions to their resin portfolio, Cytiva has taken a holistic approach to serving their chromatography customers. Establishing manufacturing close to where customers are making their therapeutics is a priority for Cytiva. The second resins manufacturing site in Muskegon, Michigan, is on track to be fully operational by end of 2028.
Protein A resin cost – Cytiva analysis
Resins manufacturing expansion in Muskegon, Michigan
See the history of Sephadex
Protein separation on Discovery Matters podcast
Protein A on Discovery Matters podcast
More on our chromatography portfolio here
Cytiva, MabSelect, MabSelect PrismA, and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
About Cytiva
At Cytiva, a Danaher company, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Original source here.